Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263404 | PMC |
| http://dx.doi.org/10.1016/j.esmoop.2022.100532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis" [Cancer Lett. 520 (2021) 321-331].
Cancer Lett
August 2023
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].
ESMO Open
August 2022
Department of Thoracic and Breast Surgery, Oita University, Oita, Japan.
Corrigendum to 'A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC)'.
EBioMedicine
April 2021
Laboratory of Precision Oncology and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome #02-01, Singapore 138672, Singapore. Electronic address:
Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].
Cancer Lett
November 2020
Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address:
[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.
Oncol Rep
January 2019
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
The AKT inhibitor employed in this article was identified as MK 2206 (8‑[4‑(1‑aminocyclobutyl) phenyl]‑9‑phenyl‑1,2,4‑ triazolo[3,4‑f][1,6]naphthyridin‑3(2H)‑one hydrochloride (1:2). However, another AKT inhibitor was actually used, which is typically identified as Akt I‑1,2 (HC,I. IPA (2‑[4‑(3‑phenylquinoxalin‑2‑yl)phenyl]propan‑2‑amine hydrochloride isopropanol (1:1:1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!